当前蛋白身份:P33552 重新检索
本组结构的主要差异维度
突变/修饰不同 组装状态不同 配体/离子不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
1CKS HUMAN CKSHS2 ATOMIC STRUCTURE: A ROLE FOR ITS HEXAMERIC ASSEMBLY IN CELL CYCLE CONTROL 提交 1993-09-16 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 1–79(79 aa)
链 B 1–79(79 aa)
链 C 1–79(79 aa)
未记录 SO4 SULFATE ION × 6 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.10 Å
4Y72 Human CDK1/CyclinB1/CKS2 With Inhibitor 提交 2015-02-13 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:TRIMERIC(3) 与蛋白数一致
链 C 1–79(79 aa) 片段:residues 165-433
未记录 LZ9 {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;pH 6.7;277 K;Conditions around 0.1M MES/imidazole buffer (pH6.7), 6.5% MPD, 5% PEG4K, 10% PEG1K Protein at 10-12 mg/ml
分辨率 2.30 Å R-free 0.252
4YC3 CDK1/CyclinB1/CKS2 Apo 提交 2015-02-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 C 1–79(79 aa)
未记录 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;pH 6.7;277 K;0.1M MES/imidazole buffer (pH6.7), 6.5% MPD, 5% PEG4K, 10% PEG1K Protein at 10-12 mg/ml
分辨率 2.70 Å R-free 0.260
5HQ0 Ternary complex of human proteins CDK1, Cyclin B and CKS2, bound to an inhibitor 提交 2016-01-21 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 C 1–79(79 aa)
未记录 LZ9 {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.7;277 K;0.1 M MES pH6.7, 6.55 MPD, 5% PEG4K, 10% PEG 1K
分辨率 2.30 Å R-free 0.252
5LQF CDK1/CyclinB1/CKS2 in complex with NU6102 提交 2016-08-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 C 1–79(79 aa)
未记录 4SP O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.7;277 K;0.1M MES/IMIDAZOLE BUFFER (PH6.7), 6.5% MPD, 5% PEG4K, 10% PEG1K PROTEIN AT 10-12 MG/ML
分辨率 2.06 Å R-free 0.254
5LQF CDK1/CyclinB1/CKS2 in complex with NU6102 提交 2016-08-17 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 1–79(79 aa)
未记录 4SP O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.7;277 K;0.1M MES/IMIDAZOLE BUFFER (PH6.7), 6.5% MPD, 5% PEG4K, 10% PEG1K PROTEIN AT 10-12 MG/ML
分辨率 2.06 Å R-free 0.254
6GU2 CDK1/CyclinB/Cks2 in complex with Flavopiridol 提交 2018-06-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 C 1–79(79 aa)
未记录 F9Z 2-(2-chlorophenyl)-8-[(3~{R},4~{R})-1-methyl-3-oxidanyl-piperidin-4-yl]-5,7-bis(oxidanyl)chromen-4-one × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;0.1M MES/IMIDAZOLE BUFFER (PH6.7), 6.5% MPD, 5% PEG4K, 10% PEG1K PROTEIN AT 10-12 MG/ML + 0.5mM Inhibitor
分辨率 2.00 Å R-free 0.239
6GU3 CDK1/CyclinB/Cks2 in complex with AZD5438 提交 2018-06-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 C 1–79(79 aa)
未记录 FB8 4-(2-methyl-3-propan-2-yl-imidazol-4-yl)-~{N}-(4-methylsulfonylphenyl)pyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;0.1M MES/IMIDAZOLE BUFFER (PH6.7), 6.5% MPD, 5% PEG4K, 10% PEG1K PROTEIN AT 10-12 MG/ML + 0.5mM Inhibitor
分辨率 2.65 Å R-free 0.258
6GU4 CDK1/CyclinB/Cks2 in complex with CGP74514A 提交 2018-06-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 C 1–79(79 aa)
未记录 FC8 ~{N}2-[(1~{R},2~{S})-2-azanylcyclohexyl]-~{N}6-(3-chlorophenyl)-9-ethyl-purine-2,6-diamine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;0.1M MES/IMIDAZOLE BUFFER (PH6.7), 6.5% MPD, 5% PEG4K, 10% PEG1K PROTEIN AT 10-12 MG/ML + 0.5mM Inhibitor
分辨率 2.73 Å R-free 0.253
6GU6 CDK1/Cks2 in complex with Dinaciclib 提交 2018-06-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 1–79(79 aa)
未记录 1QK 3-[({3-ethyl-5-[(2S)-2-(2-hydroxyethyl)piperidin-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl}amino)methyl]-1-hydroxypyridinium × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;CONDITIONS AROUND 0.1M BIS-TRIS(PH6.5), 0.2M SODIUM NITRATE 20% PEG3350, PROTEIN AT 10-12 MG/ML, 0.5Mm INHIBITOR
分辨率 2.33 Å R-free 0.246
6GU7 CDK1/Cks2 in complex with AZD5438 提交 2018-06-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 1–79(79 aa)
未记录 FB8 4-(2-methyl-3-propan-2-yl-imidazol-4-yl)-~{N}-(4-methylsulfonylphenyl)pyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;CONDITIONS AROUND 0.1M TRIS/BICINE (PH8.5), 10% PEG8K, 20% ETHYLENE GLYCOL PROTEIN AT 10-12 MG/ML, 0.5mM INHIBITOR
分辨率 2.75 Å R-free 0.274
6GU7 CDK1/Cks2 in complex with AZD5438 提交 2018-06-19 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 1–79(79 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;CONDITIONS AROUND 0.1M TRIS/BICINE (PH8.5), 10% PEG8K, 20% ETHYLENE GLYCOL PROTEIN AT 10-12 MG/ML, 0.5mM INHIBITOR
分辨率 2.75 Å R-free 0.274
6GU7 CDK1/Cks2 in complex with AZD5438 提交 2018-06-19 Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 F 1–79(79 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;CONDITIONS AROUND 0.1M TRIS/BICINE (PH8.5), 10% PEG8K, 20% ETHYLENE GLYCOL PROTEIN AT 10-12 MG/ML, 0.5mM INHIBITOR
分辨率 2.75 Å R-free 0.274
6GU7 CDK1/Cks2 in complex with AZD5438 提交 2018-06-19 Assembly 4 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 H 1–79(79 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;CONDITIONS AROUND 0.1M TRIS/BICINE (PH8.5), 10% PEG8K, 20% ETHYLENE GLYCOL PROTEIN AT 10-12 MG/ML, 0.5mM INHIBITOR
分辨率 2.75 Å R-free 0.274